Art Benvenuto

Art is the Founding Business Advisory Board member of Targazyme. He is currently the Chairman and Chief executive Officer of Micell Technologies. Prior to being named to his current role, Art served as Chairman, Life Sciences for RA Capital Group, an advisor to venture capital firms, as well as a board member of other biotech and medical device companies. He was also an early principal and the Chairman & CEO of Advanced Tissue Sciences, Inc. (ATS), a public biotechnology firm focused on the field of Issueengineering. Prior to joining ATS, Art served as President and General Manager of Eli Lilly Canada, Inc. and was President & CEO of IVAC Corp., a medical device company previously owned by Eli Lilly (now part of Care Fusion/BD). Art also held various marketing and sales management positions within the pharmaceutical Division of Lilly as well as within the medical device subsidiary, IVAC. He holds a B.S. in Pharmacy and an honorary Doctor of Science from St. John’s University.

Art’s previous board appointments include Scripps Insitute of Medicine and Science; The Scripps Research Insitute; Scripps Memorial Hospital FoundaOon (where he served as President); Project HOPE, international health, and education foundation; La Jolla Cancer FoundaOon (now Sanford-Burnham Medical Research Insitute); Board of Overseers for the University of California, San Diego; Governor’s Council on Biotechnology (California); San Diego Economic Development CorporaOon; City NaOonal Bank (San Diego Advisory Board); and BIOCOM (San Diego), where he was a founding board member. Art has acted as a former board member and advisor to certain other privately-held and publicly-traded biomedical companies.